<ml class="zpsjo"></ml>
尊龙
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2025-06-03
Henlius Unveils Updated Phase 2 Results and Phase 3 Trial Design for Anti-HER2 mAb HLX22 in First-Line HER2+ Gastric Cancer
2025-06-01
Latest Results of Serplulimab in Lung and Gastrointestinal Cancer Released at ASCO 2025
2025-05-26
Henlius Receives Orphan Drug Designation for Its Innovative Anti-HER2 mAb HLX22 in the European Union for Gastric Cancer
2025-05-21
Henlius Strengthens Information Security with ISO/IEC 27001:2022 Certification Upgrade
2025-05-16
First Subject Dosed for Phase 1/3 Clinical Trial of Henlius’ Proposed Ipilimumab Biosimilar
2025-05-14
Henlius Included in MSCI Global Small Cap Indexes, Reinforcing Its Position in Global Capital Markets
2025-05-13
Henlius Will Be at BIO 2025
2025-05-08
Latest Results of Serplulimab in Gastric Cancer Released at IGCC 2025
2025-04-29
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
1
2
3
4
5
6
7
...
9
